<DOC>
	<DOCNO>NCT01576471</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , multicenter , proof concept study parallel group design evaluate safety efficacy oral Trichuris Suis Ova ( TSO ) suspension , compare placebo , patient moderately severely active Crohn 's disease . This study also optional open-label extension patient complete double-blind phase study .</brief_summary>
	<brief_title>Efficacy Safety Trichuris Suis Ova ( TSO ) Compared Placebo</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>1 . Patient male female , 18 65 year old . 2 . Patient establish diagnosis Crohn 's disease ( CD ) least 3 month confirm endoscopic histological , endoscopic radiological criterion . 3 . Patient localization CD either terminal ileum ( L1 ) , colon ( L2 ) ileocolitis ( L3 ) , without upper gastrointestinal involvement ( L4 ) accord Montreal classification ( 2005 ) . 4 . Patient active , symptomatic CD manifest CDAI ≥ 220 ≤ 450 Baseline . 5 . Patient active intestinal inflammation visualize endoscopy within 8 week prior Baseline . 6 . Patient use concomitant medication treatment underlie Crohn 's disease follow exception : concomitant medication may include : 1 ) Oral rectal sulfasalazine , mesalazine ( 5ASA ) , mesalazine derivative , receive &gt; 6 week receive dose least 4 week ; 2 ) Oral prednisone 15 mg/day , budesonide receive &gt; 4 week receive dose least 4 week ; 3 ) Azathioprine ( 2.5 mg/kg daily ) 6mercaptopurine ( 2 mg/kg daily ) receive &gt; 3 month receive dose least 8 week prior Baseline . 7 . Hemoglobin least 10 g/dl , normal white blood cell platelet count &gt; low limit normal screening . 8 . For female childbearing potential , negative serum pregnancy test prior enrollment , breastfeed study duration , willingness use accept form reliable birth control study duration [ include bilateral tubal ligation , use oral contraceptive , double barrier method ( diaphragm spermicidal gel condom contraceptive foam ) , DepoProvera® , hormonal implant , total abstinence ] . Pregnancy test require ( indicate `` N/A '' ) males female childbearing potential ( postmenopausal last menstrual period &gt; 1 year ago total hysterectomy ) . 9 . Patient ability provide inform consent . 1 . Patient known Crohn 's lesion upper GItract ( esophagus , stomach , duodenum , jejunum ) present symptom . 2 . Patient ulcerative colitis , indeterminate colitis , ulcerative proctitis . 3 . Bowel surgery past 6 month prior Screening . 4 . Resection 50 cm ileum . 5 . Current ileostomy colostomy . 6 . Ongoing active septic complication , hospitalize exhibit sign toxicity ( sepsis ) , symptomatic stricture , impend obstruction anticipate need blood transfusion gastrointestinal bleeding surgical intervention may imminent . 7 . Patient gastrointestinal abscess perforation . 8 . Patient fistulae new onset within 2 month Screening moderate severe local inflammation . 9 . Patient history colorectal cancer colorectal dysplasia . Patients completely resect sporadic adenoma may enrol . 10 . Patient require parenteral tube feeding . 11 . Patient current evidence infectious colitis , e.g. , Clostridium difficile , Amoebiasis , Giardia lamblia stool positive enteric pathogen , ova parasite Screening . 12 . Female patient pregnant breastfeeding wish become pregnant study participation unwilling use birth control . 13 . Patient serum creatinine ≥ 2.0 mg/dL ; blood urea nitrogen &gt; 40 mg/dL ; alkaline phosphatase &gt; 250 U/L ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 100 U/L ; total bilirubin &gt; 1.5 mg/dL . 14 . Patient hepatitis B virus , hepatitis C virus , liver cirrhosis portal hypertension , know human immunodeficiency virus ( HIV ) positive . 15 . Patient primary sclerosing cholangitis . 16 . Patient malignancy within past 5 year , exception completely excise squamous basal cell skin cancer , cervical carcinoma situ . 17 . Patient receive cyclosporine , antiTNFα immunomodulatory agent azathioprine/6mercaptopurine within 12 week prior Screening . 18 . Patient primary nonresponder antiTNFα . 19 . Patient refractory azathioprine/6mercaptopurine . 20 . Patient receive methotrexate within 6 week prior Screening . 21 . Patient receive metronidazole within 2 week prior Screening . 22 . Patient receive nonsteroidal antiinflammatory drug ( NSAIDS ) within 2 week Baseline visit 3 consecutive day , except acetylsalicylic acid ≤ 350 mg/d allow . 23 . Patient receive antibiotic , antifungal antiparasitic medication last 2 week prior Screening and/or would potentially require study treatment period . 24 . Patient history drug alcohol abuse within 6 month prior Screening . 25 . Patient evidence poor compliance medical advice instruction include diet medication . 26 . Patient unable unwilling swallow study medication suspension . 27 . Patient significant medical condition put patient risk study participation and/or reason consider Investigator unsuitable patient receive CNDO201 TSO potentially put risk study procedure . 28 . Patient participate another clinical trial within 30 day Screening trial and/or experimental treatment population .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>T. suis ovum</keyword>
	<keyword>Trichuris suis ovum</keyword>
	<keyword>Inflammatory Bowel Disease</keyword>
	<keyword>TRUST-I</keyword>
	<keyword>TRUSTI</keyword>
	<keyword>TRUST-1</keyword>
	<keyword>TRUST1</keyword>
</DOC>